FMC continues to face crop protection destocking pressure with generic competition eroding diamides franchise margins. Channel inventory normalization has taken longer than guided. Biologicals segment growth helpful but not enough to offset legacy headwinds. Patent expirations on key products tighten the medium-term outlook.
Thesis reviewed May 29, 2026
FMC Corporation is headquartered in United States, which is currently showing elevated risk signals.
πΊπΈUnited States78REDUCEView United States risk detail βπΎAgriculture17REDUCE| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| NTR | Nutrien Ltd. | 24 | +11% | β85% | EARLY |
| DE | Deere & Company | 24 | +6% | β85% | NEUTRAL |
| TSN | Tyson Foods Inc. | 24 | -11% | β85% | AVOID |
| ICL | ICL Group Ltd. | 24 | +14% | β85% | EARLY |
| ANDE | The Andersons, Inc. | 24 | +7% | β85% | NEUTRAL |
| BG | Bunge Global SA | 24 | +12% | β85% | EARLY |
| FMC | FMC Corporation | 24 | -6% | β85% | AVOID |
Investors who hold FMC may also have indirect exposure through these country funds.
FMC lowers FY26 guidance citing pricing pressure on diamides
Generic chlorantraniliprole supply expands into Brazil season
Estimates Β· Yahoo Finance Β· Not audited figures